Buffalo (1)

Acute Myeloid Leukemia (1)

Blasts 30 Percent or Less of Bone Marrow Nucleated Cells (1)

Chronic Myelomonocytic Leukemia (1)

High Risk Myelodysplastic Syndrome (1)

Myelodysplastic Syndrome (1)

Refractory Anemia (1)

Completed (1)

phase 1 (1)

Roswell Park Cancer Institute (1)

Celldex Therapeutics (1)

dec-205/ny-eso-1 fusion protein cdx-1401 (1)

decitabine (1)

laboratory biomarker analysis (1)

nivolumab (1)

poly iclc (1)

biological (1)

drug (1)

other (1)

Other (1)

Interventional (1)

blasts 30 percent or less of bone marrow nucleated cells

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Completed

Oct 4, 2021